Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Cash and Equivalents of $3.56 billion for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.56B | +7.8% |
| 2024 | $3.30B | +2.3% |
| 2023 | $3.23B | +15.2% |
| 2022 | $2.80B | +29.4% |
| 2021 | $2.17B | -0.6% |
| 2020 | $2.18B | +10.2% |
| 2019 | $1.98B | +10.8% |
| 2018 | $1.78B | +85.0% |
| 2017 | $963.00M | -2.5% |
| 2016 | $988.00M | -85.8% |
| 2015 | $6.95B | +212.0% |
| 2014 | $2.23B | +114.5% |
| 2013 | $1.04B | -63.9% |
| 2012 | $2.88B | +162.7% |
| 2011 | $1.10B | -12.2% |
| 2010 | $1.25B | -37.4% |
| 2009 | $2.00B | +7.6% |
| 2008 | $1.85B | +24.6% |
| 2007 | $1.49B | +11.7% |
| 2006 | $1.33B | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.20B | -33.6% | +1.9% |
| June 30, 2025 | $2.16B | -4.3% | +27.3% |
| March 31, 2025 | $1.70B | -43.3% | -48.6% |
| December 31, 2024 | $3.30B | +2.3% | -0.6% |
| September 30, 2024 | $3.32B | +47.6% | +47.0% |
| June 30, 2024 | $2.26B | -15.4% | -24.5% |
| March 31, 2024 | $2.99B | +39.6% | -7.3% |
| December 31, 2023 | $3.23B | +15.2% | +43.4% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +7.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2025 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s cash and equivalents has grown by 167.0% (from $1.33 billion to $3.56 billion).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: